Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elacytarabine

Next Previous
X
Search
Drug Profile

Elacytarabine

Alternative Names: CP-4055; ELACYT™; UNII-TA7WJG93AR

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clavis Pharma
  • Developer Aqualis; Clavis Pharma
  • Class Antineoplastics; Arabinonucleosides; Oleic acids; Pyrimidine nucleosides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Colorectal cancer; Malignant melanoma; Ovarian cancer

Most Recent Events

  • 29 Aug 2013 Discontinued - Phase-II for Acute myeloid leukaemia (combination therapy, early-stage disease, second-line or greater) in France, Germany, Norway and USA (IV)
  • 29 Aug 2013 Discontinued - Phase-III for Acute myeloid leukaemia (late-stage disease) in Australia, Belgium, Canada, France, Germany, Ireland, Italy, Norway, Poland, Romania, Spain, United Kingdom and USA (IV)
  • 01 Apr 2013 Suspended - Phase-II for Acute myeloid leukaemia (combination therapy, second-line therapy or greater, early-stage disease) in France (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top